SWOG clinical trial number
S1107
Parallel (Randomized) Phase II Evaluation of ARQ 197 and ARQ 197 in Combination with Erlotinib in Papillary Renal Cell Carcinoma
71% Accrual
Accrual
71%
Closed
Phase
71% Accrual
Accrual
71%
Abbreviated Title
Papillary Renal, ARQ 197 +/- Erlotinib, Ph II
Activated
08/20/2012
Closed
05/29/2014
Participants
Research committees
Genitourinary Cancer
Treatment
Erlotinib
ARQ 197
Eligibility Criteria Expand/Collapse
Publication Information Expand/Collapse
Other Clinical Trials
S2312
SWOG Clinical Trial Number
Research Committee(s)
Genitourinary Cancer
Activated
09/03/2024
5% Accrual
Accrual
5%
Open
Phase
S2210
SWOG Clinical Trial Number
Research Committee(s)
Genitourinary Cancer
Activated
08/14/2023
11% Accrual
Accrual
11%
Open
Phase
S2200
SWOG Clinical Trial Number
Research Committee(s)
Genitourinary Cancer
Activated
09/19/2022
17% Accrual
Accrual
17%
Open
Phase